Request Demo
Last update 23 Jan 2025
Reconnect Labs
Last update 23 Jan 2025
Overview
Basic Info
Introduction Reconnect Labs is a spin-off of the University of Zürich, with the mission to develop innovative, rapid-acting and sustainable therapies for affective disorders (anxiety, depression, trauma, addiction), and neurodegenerative diseases. It is specialized on the development of next generation psychedelic medicines with increased safety, tolerability and efficacy in mental health applications. |
Tags
Nervous System Diseases
Other Diseases
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT06685965
Double-Blind, Randomized, Placebo-Controlled, Crossover, Laboratory Based Study With Rollover Extension to Evaluate Safety of Short-term Use of RE03 in Home Setting in Post-Traumatic Stress Disorder (PTSD) Patients With Sleep Disturbances
NCT05979727
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
NCT05829603
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
100 Clinical Results associated with Reconnect Labs
Login to view more data
Login to view more data
100 Deals associated with Reconnect Labs
Login to view more data
100 Translational Medicine associated with Reconnect Labs
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 31 Jan 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
1
Phase 2 Clinical
Other
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free